Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H19N5O2 |
Molecular Weight | 385.4186 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1N2N=CC(C(=O)C3=CC=CC(=C3)C#N)=C2N)C(=O)NC4CC4
InChI
InChIKey=VGUSQKZDZHAAEE-UHFFFAOYSA-N
InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29)
Molecular Formula | C22H19N5O2 |
Molecular Weight | 385.4186 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Acumapimod (BCT-197) is an oral p38 MAP kinase inhibitor and an anti-inflammatory agent developed by Mereo BioPharma that has completed Phase 2 development as first-line therapy for severe acute exacerbations of chronic obstructive pulmonary disease. Another study on acute kidney injury in patients undergoing cardiac surgery had been discontinued. Acumapimod is an inhibitor of p38a with an IC50 value < 1 uM. Previous studies undertaken by Novartis, showed the drug has the capacity to reduce the inflammatory marker TNFα and to increase FEV1.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: LPS‐induced TNFα secretion Sources: https://www.ncbi.nlm.nih.gov/pubmed/26904383 |
115.0 nM [IC50] | ||
Target ID: CHEMBL260 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26904383 |
12.0 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25599809
The effects of single doses of 20 and 75 mg acumapimod ± prednisone, were investigated in COPD patients
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25599809
Acumapimod is an inhibitor of p38a with an IC50 value < 1 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:28:07 GMT 2023
by
admin
on
Sat Dec 16 08:28:07 GMT 2023
|
Record UNII |
2F16KW647L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11338127
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY | |||
|
DB15448
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY | |||
|
300000025633
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY | |||
|
C166567
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY | |||
|
836683-15-9
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545226
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY | |||
|
2F16KW647L
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY | |||
|
9917
Created by
admin on Sat Dec 16 08:28:07 GMT 2023 , Edited by admin on Sat Dec 16 08:28:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |